Liquid dosage forms extemporaneously prepared from commercially available products - Considering new evidence on stability

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 3, 2013, Pages 441-455

  Haywood, Alison ^a   Glass, Beverley D ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; APREPITANT; CELECOXIB; CLOPIDOGREL; CLOZAPINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE SODIUM PHOSPHATE; ETIRACETAM; GLYCOPYRRONIUM BROMIDE; LANSOPRAZOLE; MELATONIN; MERCAPTOPURINE; MOXIFLOXACIN; OMEPRAZOLE; OSELTAMIVIR; OXANDROLONE; PHENOBARBITAL; RIFAXIMIN; RUFINAMIDE; SALAZOSULFAPYRIDINE; SUNITINIB; TACROLIMUS; TADALAFIL; TEMOZOLOMIDE; THALIDOMIDE; TIOGUANINE; UNINDEXED DRUG; VANCOMYCIN; VENLAFAXINE; WARFARIN;

DRUG DOSAGE FORM; DRUG FORMULATION; DRUG PACKAGING; DRUG QUALITY; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; EXCIPIENT COMPATIBILITY; LIQUID DOSAGE FORM; PALATABILITY; PHYSICAL CHEMISTRY; REVIEW; SHELF LIFE;

EID: 84880048430     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j38887     Document Type: Review

References (70)

1. Trissel LA. 2009. Trissel's Stability of Compounded Formulations. 4th ed. ed., Washington, DC: American Pharmacists Association.
2. Kawamura O, Easterling C, Aslam M, Rittmann T, Hofmann C, Shaker R 2004. Laryngo-upper esophageal sphincter contractile reflex in humans deteriorates with age. Gastroenterology 127(1):57-64.
3. Morris H 2005. Administering drugs to patients with swallowing difficulties. Nursing Times 101(39):28-30.
4. Ren J, Xie P, Lang IM, Bardan E, Sui Z, Shaker R 2000. Deterioration of the pharyngo-UES contractile reflex in the elderly. Laryngoscope 110(9):1563-1566.
5. Voudrie MA, Allen DB 2010. Stability of Oseltamivir Phosphate in SyrSpend SF, Cherry Syrup, and SyrSpend SF (For Reconstitution). IJPC 14(1):82-85.
6. Winiarski AP, Infeld MH, Tscherne R, Bachynsky M, Rucki R, Nagano-Mate K 2007. Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. J Am Pharm Assoc (2003) 47(6):747-755.
7. Glass BD, Haywood A 2006. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products. Journal of Pharmacy and Pharmaceutical Sciences 9(3):398-426.
8. Fohl AL, Johnson CE, Cober MP 2011. Stability of extemporaneously prepared acetylcysteine 1% and 10% solutions for treatment of meconium ileus. Am J Health Syst Pharm 68(1):69-72.
9. Kiser TH, Oldland AR, Fish DN 2007. Stability of acetylcysteine solution repackaged in oral syringes and associated cost savings. Am J Health Syst Pharm 64(7):762-766.
10. Siden R, Johnson CE 2008. Stability of a flavored formulation of acetylcysteine for oral administration. Am J Health Syst Pharm 65(6):558-561.
11. Dupuis LL, Lingertat-Walsh K, Walker SE 2009. Stability of an extemporaneous oral liquid aprepitant formulation. Support Care Cancer 17(6):701-706.
12. Donnelly RF, Pascuet E, Ma C, Vaillancourt R 2009. Stability of celecoxib oral suspension. Can J Hosp Pharm 62(6):464-468.
13. Skillman KL, Caruthers RL, Johnson CE 2010. Stability of an extemporaneously prepared clopidogrel oral suspension. Am J Health Syst Pharm 67(7):559-561.
14. Mihaila B, Ellis D, Rozek T, Milne R 2012. Chiral Stability Study of Oral Liquid Clopidogrel Formulations for Infants. J Pharm Prac Res 42(2):106-110.
15. Walker SE, Baker D, Law S 2005. Stability of clozapine stored in oral suspension vehicles at room temperature. Can J Hosp Pharm 58(5):279-284.
16. Kennedy R, Groepper D, Tagen M, Christensen R, Navid F, Gajjar A, Stewart CF 2010. Stability of cyclophosphamide in extemporaneous oral suspensions. Ann Pharmacother 44(2):295-301.
17. Chou J, Decarie D, Dumont RJ, Ensom MH 2001. Stability of dexamethasone in extemporaneously prepared oral suspensions. Can J Hosp Pharm 54(2):97-103.
18. Cober MP, Johnson CE, Sudekum D, Penprase K 2011. Stability of extemporaneously prepared glycopyrrolate oral suspensions. Am J Health Syst Pharm 68(9):843-845.
19. Ensom MH, Decarie D, Sheppard I 2007. Stability of lansoprazole in extemporaneously compounded suspensions for nasogastric or oral administration. Can J Hosp Pharm 60(3):184-191.
20. Melkoumov A, Soukrati A, Elkin I, Forest JM, Hildgen P, Leclair G 2011. Quality evaluation of extemporaneous delayed-release liquid formulations of lansoprazole. Am J Health Syst Pharm 68(21):2069-2074.
21. Ensom MH, Decarie D, Rudolph S 2011. Stability of levetiracetam in extemporaneously compounded suspensions. Can J Hosp Pharm 64(3):207-211.
22. Johnson CE, Cober MP, Thome T, Rouse E 2011. Stability of an extemporaneous alcohol-free melatonin suspension. Am J Health Syst Pharm 68(5):420-423.
23. Aliabadi HM, Romanick M, Desai S, Lavasanifar A 2008. Effect of buffer and antioxidant on stability of a mercaptopurine suspension. Am J Health Syst Pharm 65(5):441-447.
24. Hutchinson DJ, Johnson CE, Klein KC 2009. Stability of extemporaneously prepared moxifloxacin oral suspensions. Am J Health Syst Pharm 66(7):665-667.
25. Johnson CE, Cober MP, Ludwig JL 2007. Stability of partial doses of omeprazole-sodium bicarbonate oral suspension. Ann Pharmacother 41(12):1954-1961.
26. Burnett JE, Balkin ER 2006. Stability and viscosity of a flavored omeprazole oral suspension for pediatric use. Am J Health Syst Pharm 63(22):2240-2247.
27. Johnson CE, Cober MP, Hawkins KA, Julian JD 2011. Stability of extemporaneously prepared oxandrolone oral suspensions. Am J Health Syst Pharm 68(6):519-521.
28. Cober MP, Johnson CE 2007. Stability of an extemporaneously prepared alcohol-free phenobarbital suspension. Am J Health Syst Pharm 64(6):644-646.
29. Caruthers RL, Johnson CE 2007. Stability of extemporaneously prepared sodium phenylbutyrate oral suspensions. Am J Health Syst Pharm 64(14):1513-1515.
30. Cober MP, Johnson CE, Lee J, Currie K 2010. Stability of extemporaneously prepared rifaximin oral suspensions. Am J Health Syst Pharm 67(4):287-289.
31. Hutchinson DJ, Liou Y, Best R, Zhao F 2010. Stability of extemporaneously prepared rufinamide oral suspensions. Ann Pharmacother 44(3):462-465.
32. Lingertat-Walsh K, Walker SE, Law S, Abesamis M, Sales P 2006. Stability of Sulfasalazine Oral Suspension. Can J Hosp Pharm 59(4):194-200.
33. Navid F, Christensen R, Minkin P, Stewart CF, Furman WL, Baker S 2008. Stability of sunitinib in oral suspension. Ann Pharmacother 42(7):962-966.
34. Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, Padmanabhan S, Battiwalla M, McCarthy PL 2006. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplant 37(8):781-784.
35. Pettit RS, Johnson CE, Caruthers RL 2012. Stability of an extemporaneously prepared tadalafil suspension. Am J Health Syst Pharm 69(7):592-594.
36. Trissel LA, Zhang Y, Koontz S 2006. Temozolomide Stability in Extemporaneously Compounded Oral Suspensions. International Journal of Pharmaceutical Compounding 10(5):396-399.
37. Kraft S, Johnson CE, Tyler RP 2012. Stability of an extemporaneously prepared thalidomide suspension. Am J Health Syst Pharm 69(1):56-58.
38. Hopkins AM, Sharley NA, Tang CD 2012. Stability Study of a Thalidomide Suspension. J Pharm Prac Res 42(2):115-117.
39. Aliabadi HM, Romanick M, Somayaji V, Mahdipoor P, Lavasanifar A 2011. Stability of compounded thioguanine oral suspensions. Am J Health Syst Pharm 68(10):900-908.
40. Whaley PA, Voudrie MA 2012. Stability of Vancomycin in SyrSpend SF. International Journal of Pharmaceutical Compounding 16(2):167-169.
41. Donnelly RF, Wong K, Goddard R, Johanson C 2011. Stability of Venlafaxine Immediate-Release Suspensions. International Journal of Pharmaceutical Compounding 15(1):81-84.
42. Kervela G-J, Castagnet S, Chiadmi F, Schlatter J, Benabadji Z, Cisternino S, Fontan JE 2009. Assessment of stability in extemporaneously prepared venlafaxine solutions. european Journal of Hospital Pharmacy Practice 15(4):30-32.
43. De Rosa NF, Sharley NA 2008. Stability of Venlafaxine Hydrochloride Liquid Formulations Suitable for Administration via Enteral Feeding Tubes. J Pharm Prac Res 38(3):212-215.
44. Sharley NA, Yu AMC, Williams DB 2007. Stability of Mixtures Formulated from Warfarin Tablets or Powder. J Pharm Prac Res 37(2):95-97.
45. Green K, Parish RC 2010. Stability of ziprasidone mesylate in an extemporaneously compounded oral solution. J Pediatr Pharmacol Ther 15(2):138-141.
46. Abobo CV, Wei B, Liang D 2009. Stability of zonisamide in extemporaneously compounded oral suspensions. Am J Health Syst Pharm 66(12):1105-1109.
47. Babu NJ, Sanphui P, Nangia A 2012. Crystal engineering of stable temozolomide cocrystals. Chem Asian J 7(10):2274-2285.
48. DiGiacinto JL, Olsen KM, Bergman KL, Hoie EB 2000. Stability of suspension formulations of lansoprazole and omeprazole stored in ambercolored plastic oral syringes. Ann Pharmacother 34(5):600-605.
49. Ghulam A, Keen K, Tuleu C, Wong IC, Long PF 2007. Poor preservation efficacy versus quality and safety of pediatric extemporaneous liquids. Ann Pharmacother 41(5):857-860.
50. Salgado AC, Rosa ML, Duarte MA, Almeida AJ 2005. Stability of spironolactone in an extemporaneously prepared aqueous suspension: the importance of microbiological quality of compounded paediatric formulations. Eur J Hosp Pharm Sci 11(3):68-73.
51. Shah RB, Prasanna HR, Rothman B, Khan MA 2008. Stability of ranitidine syrup re-packaged in unit-dose containers. Am J Health Syst Pharm 65(4):325-329.
52. Milne CP, Bruss JB 2008. The economics of pediatric formulation development for off-patent drugs. Clin Ther 30(11):2133-2145.
53. Lowey A, Jackson M 2008. How to ensure the quality and safety of unlicensed oral medicines. The Pharmaceutical Journal 281:240.
54. US Pharmacopeia-National Formulary (USP 36-NF 31) Online. NF monographs: Vehicle for Oral Solution, Vehicle for Oral Solution Sugar Free and Vehicle for Oral Suspension. ed., Rockville, MD: United States Pharmacopeial Convention.
55. Helin-Tanninen M, Autio K, Keski-Rahkonen P, Naaranlahti T, K. J 2012. Comparison of six different suspension vehicles in compounding of oral extemporaneous nifedipine suspension for paediatric patients. European journal of hospital pharmacy doi:10.1136/ejhpharm-2011-000159
56. Lam MS 2011. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs. Pharmacotherapy 31(2):164-192.
57. Allen LVJ. 2003. Allen's compounded formulations: the complete US pharmacist collection. ed., Washington DC: American Pharmaceutical Association.
58. Nahata MC, Pai VB. 2011. Pediatric drug formulations. 6th ed. ed., Cincinnati.
59. Emergency Compounding of an Oral Suspension from Tamiflu 75 mg Capsules (Final Concentration 15 mg/mL). http://www.fda.gov/Drugs/DrugSafety/Postmarket DrugSafetyInformationforPatientsandProviders/uc m183878.htm [accessed: 11/03/2013]. ed.
60. Tamiflu. Extemporaneous Preparation. http://www.tamiflu.com/hcp/resources/hcp_resour ces_pharmacists.jsp [accessed: 11/03/2013]. ed.
61. Prinivil(r) tablets. http://www.merck.com/product/usa/pi_circulars/p/ prinivil/prinivil_pi.pdf [accessed: 11/03/2013]. ed.
62. Zestril(r) tablets. http://www1.astrazenecaus. com/pi/zestrillpv.pdf [accessed: 11/03/2013]. ed.
63. Rifadin(r) capsule. http://dailymed.nlm.nih.gov/dailymed/archives/fda DrugInfo.cfm?archiveid=8618 [accessed: 11/03/2013]. ed.
64. Burridge N, Deidun D. 2012. Australian Don't Rush to Crush Handbook. ed., Collingwood: Society of Hospital Pharmacists of Australia. p 650.
65. White R, Bradnam V. 2007. Handbook of Drug Administration via Enteral Feeding Tubes. ed., London: Pharmaceutical Press.
66. AMH. 2006. Australian medicines handbook. Drug Choice Companion: Aged Care, 2nd ed. ed., Adelaide: Australian Medicines Handbook Pty Ltd.
67. Mitchell JF. 2011. Oral dosage forms that should not be crushed. Institute for Safe Medication Practices, 7 July 2011, Available from www.ismp.org/tools/donotcrush.pdf. ed.
68. Dansereau RJ, Crail DJ 2008. Compatibility of risedronate sodium tablets with food thickeners. Am J Health Syst Pharm 65(22):2133-2136.
69. Nahata MC, Morosco RS, Leguire LE 2000. Development of two stable oral suspensions of levodopa-carbidopa for children with amblyopia. J Pediatr Ophthalmol Strabismus 37(6):333-337.
70. Lim LY, Tan LL, Chan EW, Yow KL, Chan SY, Ho PC 1997. Stability of phenoxybenzamine hydrochloride in various vehicles. Am J Health Syst Pharm 54(18):2073-2078.